Manufacturing Vaccines in Adherent Cell Lines Using Disposable Multi-tray Bioreactors - By allowing a single system to be used from laboratory- to commercial-scale, multi-tray bioreactors can facilita

ADVERTISEMENT

Manufacturing Vaccines in Adherent Cell Lines Using Disposable Multi-tray Bioreactors
By allowing a single system to be used from laboratory- to commercial-scale, multi-tray bioreactors can facilitate scale up and accelerate vaccine development.


BioPharm International


References:

1 Cesano A, Visonneau S, Jeglum KA, Owen J, Wilkinson K, Carner K, et al. Phase i clinical trial with a human major histocompatibility complex nonrestricted cytotoxic t-cell line (tall-104) in dogs with advanced tumors. Cancer Res. 1996; 56:3021–3029.

2. Schwander E, Ramusen, H. Manufacturing of lots of human T lymphocytes for cell therapy: A new process based on disposable bioreactors. Gen Eng News. 2005 Apr 15; 25(8).

3. Schlenke P, et al. Serum-free transient expression of antibodies using 40 tray cell factories. Poster. Laupheim, Germany: Renschler Biotechnologie Gmbh.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here